These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 25442041)

  • 1. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
    Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
    Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
    Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.
    Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Cassoni P; Arena V; Bustreo S; Faletti R; Rondi N; Morino M; Ricardi U
    Med Oncol; 2016 Jul; 33(7):72. PubMed ID: 27277756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis.
    Carpenter DJ; Jacobs CD; Wong TZ; Craciunescu O; Chino JP
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):356-366. PubMed ID: 31254659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
    Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
    Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer.
    Kuncman Ł; Stawiski K; Masłowski M; Kucharz J; Fijuth J
    Strahlenther Onkol; 2020 Nov; 196(11):998-1005. PubMed ID: 32621010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.
    Rose BS; Jee KW; Niemierko A; Murphy JE; Blaszkowsky LS; Allen JN; Lee LK; Wang Y; Drapek LC; Hong TS; Wo JY
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):747-54. PubMed ID: 26972647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in cervical cancer FDG uptake during chemoradiation and association with response.
    Kidd EA; Thomas M; Siegel BA; Dehdashti F; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):116-22. PubMed ID: 22520475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
    Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
    Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer.
    Lee JW; Jeon S; Mun ST; Lee SM
    Int J Gynecol Cancer; 2017 May; 27(4):776-783. PubMed ID: 28333846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy.
    Noticewala SS; Li N; Williamson CW; Hoh CK; Shen H; McHale MT; Saenz CC; Einck J; Plaxe S; Vaida F; Yashar CM; Mell LK
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):797-805. PubMed ID: 28244416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating
    Franco P; Fiandra C; Arcadipane F; Trino E; Giglioli FR; Ragona R; Ricardi U
    BMC Cancer; 2017 Nov; 17(1):710. PubMed ID: 29096619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
    Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
    Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A methodology for incorporating functional bone marrow sparing in IMRT planning for pelvic radiation therapy.
    McGuire SM; Menda Y; Ponto LL; Gross B; Juweid M; Bayouth JE
    Radiother Oncol; 2011 Apr; 99(1):49-54. PubMed ID: 21397965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
    Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
    Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.